Cited by 826Atrial Fibrillation Management and OutcomesBlood Pressure and Hypertension StudiesCardiac electrophysiology and arrhythmias

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Open access

Wachtell, Kristian, Lehto, Mika, Gerdts, Eva, Olsen, Michael H., Hornestam, Björn, Dahlöf, Björn, Ibsen, Hans, Julius, Stevo, Kjeldsen, Sverre E., Lindholm, Lars H., Nieminen, Markku S., Devereux, Richard B.·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2004.10.068

Open this paper in CoChat — free account Open PDF

Abstract

Objectives This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF).Background It is unknown whether angiotensin II receptor blockade is better than beta-blockade in preventing new-onset AF.Methods In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 9,193 hypertensive patients and patients with electrocardiogram-documented left ventricular hypertrophy were randomized to once-daily losartan- or atenolol-based antihypertensive therapy. Electrocardiograms were Minnesota coded centrally, and 8,851 patients without AF by electrocardiogram or history, who were thus at risk of developing AF, were followed for 4.8 +/- 1.0 years.Results New-onset AF occurred in 150 patients randomized to losartan versus 221 to atenolol (6.8 vs. 10.1 per 1,000 person-years; relative risk 0.67, 95% confidence interval [CI] 0.55 to 0.83, p < 0.001) despite similar blood pressure reduction. Patients receiving losartan tended to stay in sinus rhythm longer (1,809 +/- 225 vs. 1,709 +/- 254 days from baseline, p = 0.057) than those receiving atenolol. Moreover, patients with new-onset AF had two-, three- and fivefold increased rates, respectively, of cardiovascular events, stroke, and hospitalization for heart failure. There were fewer composite end points (n = 31 vs. 51, hazard ratio = 0.60, 95% CI 0.38 to 0.94, p = 0.03) and strokes (n = 19 vs. 38, hazard ratio = 0.49, 95% CI 0.29 to 0.86, p = 0.01) in patients who developed new-onset AF in the losartan compared to the atenolol treatment arm of the study. Furthermore, Cox regression analysis showed that losartan (21% risk reduction) and new-onset AF both independently predicted stroke even when adjusting for traditional risk factors.Conclusions Our novel finding is that new-onset AF and associated stroke were significantly reduced by losartan- compared to atenolol-based antihypertensive treatment with similar blood pressure reduction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2004.10.068

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citation
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01236-6 · Cited by 1,562
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,362
Left Atrial Size and the Risk of Stroke and Death
Benjamin, E. J., D’Agostino, R. B., Belanger, A. J., Wolf, P. A., & Levy, D. A. (1995) · Circulation · doi:10.1161/01.cir.92.4.835 · Cited by 1,058
Effects of Angiotensin-Converting Enzyme Inhibition on the Development of the Atrial Fibrillation Substrate in Dogs With Ventricular Tachypacing–Induced Congestive Heart Failure
Li, D., Shinagawa, K., Pang, L., Leung, T. K., Cardin, S., Wang, Z., & Nattel, S. (2001) · Circulation · doi:10.1161/hc4601.099402 · Cited by 702
Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study
Madrid, A. H., Bueno, M. G., Rebollo, J. M. G., Marín, I., Peña, G., Bernal, E., Rodriguez, A., Cano, L., Cano, J. M., Cabeza, P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000022665.18619.83 · Cited by 685
Trandolapril Reduces the Incidence of Atrial Fibrillation After Acute Myocardial Infarction in Patients With Left Ventricular Dysfunction
Pedersen, O. D., Bagger, H., Køber, L., & Torp-Pedersen, C. T. (1999) · Circulation · doi:10.1161/01.cir.100.4.376 · Cited by 656
Enalapril Decreases the Incidence of Atrial Fibrillation in Patients With Left Ventricular Dysfunction
Vermès, E., Tardif, J., Bourassa, M. G., Racine, N., Lévesque, S., White, M., Guerra, P. G., & Ducharme, A. (2003) · Circulation · doi:10.1161/01.cir.0000072793.81076.d4 · Cited by 575
Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation
Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00464-9 · Cited by 472

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 201–300 of 819

Rationale and current perspective for early rhythm control therapy in atrial fibrillation
Gelder, I. C. V., Haegeli, L., Brandes, A., Heidbüchel, H., Aliot, E., Kautzner, J., Szumowski, Ł. J., Mont, L., Morgan, J. M., Willems, S., et al. (2011) · EP Europace · doi:10.1093/europace/eur192 · Cited by 61
Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions.
Munger, M. A. (2011) · PubMed Central · Cited by 61
Reverse-Remodeling Effects of Angiotensin II Type 1 Receptor Blocker in a Canine Atrial Fibrillation Model
Nakashima, H., & Kumagai, K. (2007) · Circulation Journal · doi:10.1253/circj.71.1977 · Cited by 60
The Impact of Suppressing the Renin‐Angiotensin System on Atrial Fibrillation
Kalus, J. S., Coleman, C. I., & White, C. M. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005283284 · Cited by 59
Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options
Sayın, B. Y., & Oto, A. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00260-y · Cited by 60
Left ventricular hypertrophy versus chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year-follow-up study
Tsioufis, C. P., Vezali, E., Tsiachris, D., Dimitriadis, K. S., Taxiarchou, E., Chatzis, D., Thomopoulos, C., Syrseloudis, D., Stefanadi, E., Mihas, C. C., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832401ff · Cited by 58
Hypertension and cardiac arrhythmias: a review of the epidemiology, pathophysiology and clinical implications
Yiu, K., & Tse, H. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.10 · Cited by 58
The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?
Dézsi, C. A. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0165-4 · Cited by 59
Hypertensive Heart Disease and Obesity
Saliba, L. J., & Maffett, S. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.06.003 · Cited by 58
Clinical Diagnosis of Electrical Versus Anatomic Left Ventricular Hypertrophy
Aro, A. L., & Chugh, S. S. (2016) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.115.003629 · Cited by 57
The Impact of Diet and Lifestyle on Atrial Fibrillation
Nalliah, C. J., Sanders, P., & Kalman, J. M. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1082-8 · Cited by 63
Pharmacologic Management of Atrial Fibrillation: Established and Emerging Options
Kalus, J. S. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.s6-b.10 · Cited by 57
Incidence of Atrial Fibrillation in Relation to Changing Heart Rate Over Time in Hypertensive Patients
Okin, P. M., Wachtell, K., Kjeldsen, S. E., Julius, S., Lindholm, L. H., Dahlöf, B., Hille, D. A., Nieminen, M. S., Edelman, J. M., & Devereux, R. B. (2008) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.108.795351 · Cited by 57
Self-citation
Endothelial Nitric Oxide Synthase–Independent Protective Action of Statin Against Angiotensin II–Induced Atrial Remodeling via Reduced Oxidant Injury
Yagi, S., Akaike, M., Aihara, K., Ishikawa, K., Iwase, T., Ikeda, Y., Soeki, T., Yoshida, S., Sumitomo-Ueda, Y., Matsumoto, T., et al. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.146076 · Cited by 56
Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis
Chaugai, S., Meng, W. Y., & Sepehry, A. A. (2016) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415619490 · Cited by 56
Angiotensin II and angiotensin 1–7: which is their role in atrial fibrillation?
Mascolo, A., Urbanek, K., Angelis, A. D., Sessa, M., Scavone, C., Berrino, L., Rosano, G. M. C., Capuano, A., & Rossi, F. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09837-7 · Cited by 56
Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy
Lappegård, K. T., Pop‐Purceleanu, M., van Heerde, W. L., Sexton, J., Tendolkar, I., & Pop, G. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-78 · Cited by 55
Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials
Emdin, C. A., Callender, T., Cao, J., & Rahimi, K. (2015) · EP Europace · doi:10.1093/europace/euv021 · Cited by 55
Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence
Chrysant, S. G. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001916 · Cited by 55
Effect of Candesartan and Various Inflammatory Markers on Maintenance of Sinus Rhythm After Electrical Cardioversion for Atrial Fibrillation
Tveit, A., Seljeflot, I., Grundvold, I., Abdelnoor, M., Smith, P., & Arnesen, H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.01.030 · Cited by 54
Regression of Left Ventricular Hypertrophy Following Stenting of Renal Artery Stenosis
Zeller, T., Rastan, A., Schwarzwälder, U., Mueller, C. E., Frank, U., Bürgelin, K., Sixt, S., Schwarz, T., Noory, E., & Neumann, F. (2007) · Journal of Endovascular Therapy · doi:10.1177/152660280701400211 · Cited by 54
Usefulness of left atrial strain for predicting incident atrial fibrillation and ischaemic stroke in the general population
Alhakak, A. S., Biering-Sørensen, S. R., Møgelvang, R., Modin, D., Jensen, G. B., Schnohr, P., Iversen, A. Z., Svendsen, J. H., Jespersen, T., Gislason, G., et al. (2020) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeaa287 · Cited by 54
New standards in hypertension and cardiovascular risk management: focus on telmisartan
Galzerano, D. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s7857 · Cited by 53
Impaired Kidney Function and Atrial Fibrillation in Elderly Subjects
Deo, R., Katz, R., Kestenbaum, B. R., Fried, L. F., Sarnak, M. J., Psaty, B. M., Siscovick, D. S., & Shlipak, M. G. (2009) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2009.07.002 · Cited by 53
Impact of angiotensin-converting enzyme-inhibitors and angiotensin receptor blockers on long-term outcome of catheter ablation for atrial fibrillation
Tayebjee, M. H., Creta, A., Moder, S., Hunter, R. J., Earley, M. J., Dhinoja, M., & Schilling, R. (2010) · EP Europace · doi:10.1093/europace/euq284 · Cited by 53
Role of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Aldosterone Antagonists in the Prevention of Atrial and Ventricular Arrhythmias
Makkar, K. M., Sanoski, C. A., & Spinler, S. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.1.31 · Cited by 53
Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives.
Sensi, F. D., Potter, T. J. R. D., Cresti, A., Severi, S., & BREITHARDT, G. E. (2015) · PubMed Central · doi:10.3978/j.issn.2223-3652.2015.06.03 · Cited by 52
Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure
Aksnes, T. A., Flaa, A., Strand, A. H., & Kjeldsen, S. E. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000254378.26607.1f · Cited by 52
Self-citation
Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence
Disertori, M., Latini, R., Maggioni, A. P., Delise, P., Pasquale, G. D., Franzosi, M. G., Staszewsky, L. I., & Tognoni, G. (2006) · Journal of Cardiovascular Medicine · doi:10.2459/01.jcm.0000199778.85343.08 · Cited by 52
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis
Huang, G., Xu, J., Liu, J., He, Y., Nie, X.-L., Li, Q., Hu, Y., Zhao, S.-Q., Wang, M., Zhang, W., et al. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02460.x · Cited by 52
Atrial Fibrillation and Isolated Systolic Hypertension
Vagaonescu, T. D., Wilson, A. C., & Kostis, J. B. (2008) · Hypertension · doi:10.1161/hypertensionaha.108.110775 · Cited by 50
Prevention, Diagnosis, and Treatment of Hypertensive Heart Disease
Georgiopoulou, V. V., Kalogeropoulos, A. P., Raggi, P., & Butler, J. (2010) · Cardiology Clinics · doi:10.1016/j.ccl.2010.07.005 · Cited by 50
Prevalencia de fibrilación auricular y uso de fármacos antitrombóticos en el paciente hipertenso ≥ 65 años. El registro FAPRES
Morillas, P., Pallarés‐Carratalá, V., Llisterri, J. L., Sanchís, C., Sánchez, T., Fácila, L., Pérez‐Alonso, M., Castillo, J., Redón, J., & Bertoméu, V. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70206-2 · Cited by 49
Atrial fibrosis: an obligatory component of arrhythmia mechanisms in atrial fibrillation?
Platonov, P. G. (2017) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2017.03.009 · Cited by 49
Antihypertensive Treatment With ACE Inhibitors or -Blockers and Risk of Incident Atrial Fibrillation in a General Hypertensive Population
Heckbert, S. R., Wiggins, K. L., Glazer, N. L., Dublin, S., Psaty, B. M., Smith, N., Longstreth, W. T., & Lumley, T. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.33 · Cited by 48
Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF) Trial
Goette, A., Breithardt, G., Fetsch, T., Hanrath, P., Klein, H., Lehmacher, W., Steinbeck, G., & Meinertz, T. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727100-00005 · Cited by 48
Annual Incidence of Atrial Fibrillation and Related Factors in Adults
Iguchi, Y., Kimura, K., Shibazaki, K., Aoki, J., Kobayashi, K., Sakai, K., & Sakamoto, Y. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.030 · Cited by 47
Documento de la Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) sobre las guías ACC/AHA 2017 de hipertensión arterial
Gijón‐Conde, T., Gorostidi, M., Camafort, M., Abad-Cardiel, M., Martín-Rioboó, E., Morales‐Olivas, F. J., Vinyoles, E., Armario, P., Banegas, J. R., Coca, A., et al. (2018) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2018.04.001 · Cited by 65
Targeting Ca2 + Handling Proteins for the Treatment of Heart Failure and Arrhythmias
Njegić, A., Wilson, C., & Cartwright, E. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.01068 · Cited by 45
Genetic susceptibility, elevated blood pressure, and risk of atrial fibrillation: a Mendelian randomization study
Nazarzadeh, M., Pinho‐Gomes, A., Bidel, Z., Canoy, D., Dehghan, A., Smith-Byrne, K., Bennett, D., Smith, G. D., & Rahimi, K. (2021) · Genome Medicine · doi:10.1186/s13073-021-00849-3 · Cited by 46
The Role of Renin–Angiotensin System Blockade Therapy in the Prevention of Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
Zhang, Y., Zhang, P., Mu, Y., Gao, M., WANG, J., Wang, Y., Su, L., & Hou, Y. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.123 · Cited by 45
Effect of renin–angiotensin aldosteron system blockers on postoperative atrial fibrillation
Özaydın, M., Dede, Ö., Varol, E., Kapan, Ş., Türker, Y., Peker, O., Düver, H., & İbrişim, E. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.05.012 · Cited by 45
Cardiovascular ultrasound exploration contributes to predict incident atrial fibrillation in arterial hypertension: The Campania Salute Network
Losi, M. A., Izzo, R., Marco, M. D., Canciello, G., Rapacciuolo, A., Trimarco, V., Stabile, E., Rozza, F., Esposito, G., LUCA, N. D., et al. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.07.019 · Cited by 44
Nonantiarrhythmic drug therapy for atrial fibrillation
Murray, K. T., Mace, L. C., & Yang, Z. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2006.12.027 · Cited by 44
Comparative Evaluation of Effect of Valsartan/Amlodipine and Atenolol/Amlodipine Combinations on Atrial Fibrillation Recurrence in Hypertensive Patients With Type 2 Diabetes Mellitus
Fogari, R., Zoppi, A., Mugellini, A., Corradi, L., Lazzari, P., Preti, P. S., & Derosa, G. (2008) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e318160b42a · Cited by 43
Hypertension and left ventricular hypertrophy
Djordjevic, D. B., Koracevic, G. P., Đorđević, A. D., & Lović, D. B. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003774 · Cited by 47
Label Free C-reactive Protein Detection Based on An Electrochemical Sensor for Clinical Application
Bing, X., & Wang, G. (2017) · International Journal of Electrochemical Science · doi:10.20964/2017.07.60 · Cited by 42
Targeting the renin–angiotensin–aldosterone system in atrial fibrillation: from pathophysiology to clinical trials
Boos, C. J., & Lip, G. Y. H. (2005) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001933 · Cited by 42
JCS / JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Journal of Arrhythmia · doi:10.1002/joa3.12714 · Cited by 41
Angiotensinogen and ACE gene polymorphisms and risk of atrial fibrillation in the general population
Ravn, L. S., Benn, M., Nordestgaard, B. G., Sethi, A. A., Agerholm-Larsen, B., Jensen, G. B., & Tybjærg‐Hansen, A. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282fce3bd · Cited by 41
Atrial fibrillation and arterial hypertension: A common duet with dangerous consequences where the renin angiotensin-aldosterone system plays an important role
Seccia, T. M., Caroccia, B., Muiesan, M. L., & Rossi, G. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.01.007 · Cited by 42
Atrial fibrillation prevention: an appraisal of current evidence
Boriani, G., & Proietti, M. (2017) · Heart · doi:10.1136/heartjnl-2017-311546 · Cited by 41
Direct Pro-Arrhythmogenic Effects of Angiotensin II can be Suppressed by AT1 Receptor Blockade in Human Atrial Myocardium
von Lewinski, D., Kockskämper, J., Rübertus, S., Zhu, D., Schmitto, J. D., Schöndube, F. A., Hasenfuss, G. P., & Pieske, B. M. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.09.014 · Cited by 39
Inflammation and arrhythmias: potential mechanisms and clinical implications
Lewek, J., Kaczmarek, K. A., Cygankiewicz, I., Wranicz, J. K., & Ptaszynski, P. A. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.942286 · Cited by 39
Blood Pressure Variability and Risk of New-Onset Atrial Fibrillation
Webb, A. J. S., & Rothwell, P. M. (2010) · Stroke · doi:10.1161/strokeaha.110.589531 · Cited by 39
Atrial endothelial impairment through Toll-like receptor 4 signaling causes atrial thrombogenesis
Katoh, S., Honda, S., Watanabe, T., Suzuki, S., Ishino, M., Kitahara, T., Funayama, A., Netsu, S., Sasaki, T., Shishido, T., et al. (2013) · Heart and Vessels · doi:10.1007/s00380-013-0369-3 · Cited by 39
Prevention of atrial fibrillation with renin-angiotensin system inhibitors on essential hypertensive patients: a meta-analysis of randomized controlled trials
Zhao, D., Wang, Z., & Wang, L. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.29.20140149 · Cited by 38
The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study
Kjeldsen, S. E., Lyle, P. A., Kizer, J. R., Dahlöf, B., Devereux, R. B., Julius, S., Beevers, G., Fairé, U. D., Fyhrquist, F., Ibsen, H., et al. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04254.x · Cited by 38
Self-citation
Angiotensin II signaling up-regulates the immediate early transcription factor ATF3 in the left but not the right atrium
Hasin, T., Elhanani, O., Abassi, Z. A., Hai, T., & Aronheim, A. (2010) · Basic Research in Cardiology · doi:10.1007/s00395-010-0145-9 · Cited by 39
The Role Of Renin Angiotensin System In Atrial Fibrillation.
Nair, G. M., Nery, P. B., Redpath, C. J., & Birnie, D. H. (2014) · PubMed Central · doi:10.4022/jafib.972 · Cited by 38
Candesartan Decreases Type III Procollagen-N-Peptide Levels and Inflammatory Marker Levels and Maintains Sinus Rhythm in Patients With Atrial Fibrillation
Kawamura, M., Ito, H., Onuki, T., Miyoshi, F., Watanabe, N., Asano, T., Tanno, K., & Kobayashi, Y. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181d70690 · Cited by 37
Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease
Maggioni, A. P. (2006) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-006-9799-9 · Cited by 38
Current Evidence-Based Understanding of the Epidemiology, Prevention, and Treatment of Atrial Fibrillation
Rogers, P. A., Bernard, M. L., Madias, C. A., Thihalolipavan, S., Estes, N. A. M., & Morin, D. P. (2017) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2017.06.001 · Cited by 36
Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention
Cuspidi, C. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.2008.04.01.67 · Cited by 36
Prevalence of Paroxysmal Atrial Fibrillation Depending on the Regression of Left Ventricular Hypertrophy in Arterial Hypertension
Hennersdorf, M., Schueller, P. O., Steiner, S., & Strauer, B. E. (2007) · Hypertension Research · doi:10.1291/hypres.30.535 · Cited by 36
The Renin‐Angiotensin System: A Therapeutic Target in Atrial Fibrillation
Patlolla, V., Alsheikh-Ali, A. A. A., & Al‐Ahmad, A. (2006) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.2006.00477.x · Cited by 36
Review: From Hypertension to Heart Failure — Are There Better Primary Prevention Strategies?
Meredith, P., & Östergren, J. (2006) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2006.012 · Cited by 36
Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study
Alings, M., Smit, M. D., Moes, M. L., Crijns, H. J. G. M., Tijssen, J. G. P., Brügemann, J., Hillege, H. L., Lane, D. A., Lip, G. Y. H., Smeets, J. L. R. M., et al. (2013) · Netherlands Heart Journal · doi:10.1007/s12471-013-0428-5 · Cited by 35
Primary stroke prevention and hypertension treatment: which is the first-line strategy?
Ravenni, R., Jabre, J. F., Casiglia, E., & Mazza, A. (2011) · Neurology International · doi:10.4081/ni.2011.e12 · Cited by 36
SYNTAX score predicts postoperative atrial fibrillation in patients undergoing on-pump isolated coronary artery bypass grafting surgery
Geçmen, Ç., Güler, G. B., Erdoğan, E., Hatipoğlu, S., Güler, E., Yılmaz, F., Unkun, T., Çap, M., Bakal, R. B., Bayram, T., et al. (2015) · The Anatolian Journal of Cardiology · doi:10.5152/anatoljcardiol.2015.6483 · Cited by 34
Left Ventricular Diastolic Dysfunction in Diabetic Patients
Tsujino, T., Kawasaki, D., & Masuyama, T. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606040-00002 · Cited by 34
Criterios electrocardiográficos de hipertrofia ventricular izquierda y perfil de riesgo cardiovascular en hipertensos. Estudio VIIDA
González‐Juanatey, J. R., Cea‐Calvo, L., Bertoméu, V., & Aznar, J. (2007) · Revista Española de Cardiología · doi:10.1157/13099461 · Cited by 34
Effects of Renin-Angiotensin System Inhibition on Left Atrial Function of Hypertensive Patients: An Echocardiographic Tissue Deformation Imaging Study
Dimitroula, H. V., Damvopoulou, E., Giannakoulas, G. A., Dalamanga, E., Dimitroulas, T., Sarafidis, P. A., Styliadis, H., Hatzitolios, A. I., Karvounis, H. I., & Parcharidis, G. E. (2010) · American Journal of Hypertension · doi:10.1038/ajh.2010.4 · Cited by 33
The Egyptian Hypertension Society
(2014) · The Egyptian Heart Journal · doi:10.1016/j.ehj.2014.03.001 · Cited by 33
Fewer Mega-Trials and More Clinically Oriented Studies in Hypertension Research? The Case of Blocking the Renin-Angiotensin-Aldosterone System
Volpe, M., Tocci, G., & Pagannone, E. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121334 · Cited by 33
Beta‐Blocker Use Is Associated With Impaired Left Atrial Function in Hypertension
Sardana, M., Syed, A. A., Hashmath, Z., Phan, T. S., Koppula, M. R., Kewan, U., Ahmed, Z., Chandamuri, R., Varakantam, S., Shah, E., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.005163 · Cited by 32
Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy
Lozano, H. F., Conde, C. A., Florin, T., & Lamas, G. A. (2005) · Heart Rhythm · doi:10.1016/j.hrthm.2005.05.020 · Cited by 32
Hypertensive Heart Disease: A Narrative Review Series—Part 2: Macrostructural and Functional Abnormalities
Nemtsova, V. D., Burkard, T., & Vischer, A. S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175723 · Cited by 31
Benefits of the RAS blockade: clinical evidence before the ONTARGET study
Perret‐Guillaume, C., Joly, L., Jankowski, P., & Bénétos, A. (2009) · Journal of Hypertension · doi:10.1097/01.hjh.0000354511.14086.f1 · Cited by 31
The addition of renal sympathetic denervation to pulmonary vein isolation reduces recurrence of paroxysmal atrial fibrillation in chronic kidney disease patients
Kiuchi, M. G., Chen, S., Silva, G. R. E., Paz, L. M. R., Kiuchi, T., Filho, A. G. D. P., & Souto, G. L. L. (2016) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-016-0186-6 · Cited by 31
Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis
Ruigómez, A., Johansson, S., Wallander, M.-A. A., Edvardsson, N. G., & Rodríguez, L. A. G. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.04.050 · Cited by 31
Mitral Annular Calcification and Incident Ischemic Stroke in Treated Hypertensive Patients: The LIFE study.
Marco, M. D., Gerdts, E., Casalnuovo, G., Migliore, T., Wachtell, K., Boman, K., Dahlöf, B., Olsen, M. H., Kizer, J. R., Devereux, R. B., et al. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hps082 · Cited by 31
Self-citation
Apocynin: a potent NADPH oxidase inhibitor for the management of atrial fibrillation
Sovari, A. A., Morita, N., & Karagueuzian, H. S. (2008) · Redox Report · doi:10.1179/135100008x309000 · Cited by 30
Catheter Ablation of Atrial Fibrillation in Heart Failure
Kirubakaran, S., & O'Neill, M. D. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.07.006 · Cited by 30
Prognostic Impact of New-Onset Atrial Fibrillation in Patients With Chronic Heart Failure – A Report From the CHART-2 Study –
Yamauchi, T., Sakata, Y., Miura, M., Tadaki, S., Ushigome, R., Sato, K., Onose, T., Tsuji, K., Abe, R., Oikawa, T., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0783 · Cited by 30
Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation
Hsieh, Y., Hung, C.-Y., Li, C.-H., Liao, Y., Huang, J., Lin, C., & Wu, T. (2016) · Medicine · doi:10.1097/md.0000000000003721 · Cited by 31
Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation
Okin, P. M., Gerdts, E., Wachtell, K., Oikarinen, L., Nieminen, M. S., Dahlöf, B., & Devereux, R. B. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e328338c20e · Cited by 30
Self-citation
Hypertension and atrial fibrillation
Go, O., & Rosendorff, C. (2009) · Current Cardiology Reports · doi:10.1007/s11886-009-0062-4 · Cited by 31
Stroke prevention in diabetes and obesity
Kurukulasuriya, L. R., Govindarajan, G., & Sowers, J. R. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.4.487 · Cited by 30
Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration
Niiranen, T., Schnabel, R. B., Schutte, A. E., Biton, Y., Boriani, G., Buckley, C. M., Cameron, A. C., Damasceno, A. A. M., Diederichsen, S. Z., Doehner, W., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.071047 · Cited by 29
ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients
Volpe, M., de la Sierra, A., Kreutz, R. H., Laurent, S., & Manolis, A. J. (2014) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-014-0043-6 · Cited by 29
Beta-blockers in atrial fibrillation—trying to make sense of unsettling results
Meyer, M., & Lustgarten, D. L. (2023) · EP Europace · doi:10.1093/europace/euad010 · Cited by 29
Atrial fibrillation and inflammation
Özaydın, M. (2010) · World Journal of Cardiology · doi:10.4330/wjc.v2.i8.243 · Cited by 29
Extracellular Matrix of Collagen Modulates Intracellular Calcium Handling and Electrophysiological Characteristics of HL-1 Cardiomyocytes With Activation of Angiotensin II Type 1 Receptor
Lu, Y., Chen, Y., Kao, Y., Wu, T.-J., Chen, Y., & Chen, Y. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.10.002 · Cited by 29
Is there any hope for angiotensin-converting enzyme inhibitors in atrial fibrillation?
Savelieva, I., & Camm, A. J. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.05.008 · Cited by 29
The influence of insulin resistance and obesity on left atrial size in Japanese hypertensive patients
Shigematsu, Y., Norimatsu, S., Ogimoto, A., Ohtsuka, T., Okayama, H., & Higaki, J. (2009) · Hypertension Research · doi:10.1038/hr.2009.41 · Cited by 28
Prognostic impact of atrial fibrillation progression in a community study: AFBAR Study (Atrial Fibrillation in the Barbanza Area Study)
García‐Castelo, A., García‐Seara, J., Otero-Raviña, F., Lado, M., Vizcaya, A., Vidal, J. M., Lafuente, R., Bouza, D., Lear, P., & González‐Juanatey, J. R. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.042 · Cited by 28
Antiarrhythmic Drug Therapy for Atrial Fibrillation
Sardar, M. R., Saeed, W., & Kowey, P. R. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.017 · Cited by 28
Guía ESC 2020 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración de la European Association of Cardio-Thoracic Surgery (EACTS)
Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J. J., Blomström‐Lundqvist, C., Boriani, G., Castellà, M., Dan, G., Dilaveris, P., et al. (2021) · Revista Española de Cardiología · doi:10.1016/j.recesp.2020.10.022 · Cited by 34
Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion
Tveit, A., Seljeflot, I., Grundvold, I., Abdelnoor, M., Arnesen, H., & Smith, P. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.10.028 · Cited by 28

Authors: Wachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., Nieminen, M. S., & Devereux, R. B.
Affiliations: Cornell University (US)
Helsinki University Hospital (FI)
Haukeland University Hospital (NO)
Glostrup Hospital (DK)
Sahlgrenska University Hospital (SE)
University of Michigan (US)
Oslo University Hospital (NO)
University Hospital of Umeå (SE)
Corresponding author: Wachtell, Kristian
ORCID: Wachtell, Kristian
Lehto, Mika
Gerdts, Eva
Olsen, Michael H.
Hornestam, Björn
Kjeldsen, Sverre E.
Lindholm, Lars H.
Nieminen, Markku S.
Devereux, Richard B.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-03
Volume: 45
Issue: 5
Pages: 712-719
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2004.10.068
OpenAlex: W2147918774
Cited by: 826
References: 27
Citations by year: 2026: 9 · 2025: 18 · 2024: 16 · 2023: 17 · 2022: 13 · 2021: 20 · 2020: 20 · 2019: 16 · 2018: 30 · 2017: 32 · 2016: 31 · 2015: 29 · 2014: 36 · 2013: 40 · 2012: 33
FWCI: 64.95
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3096 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Funders: Rigshospitalet
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
Keywords: angiotensin II receptor blockade, losartan, atenolol, beta-blockers, stroke prevention, hypertension, left ventricular hypertrophy, antihypertensive therapy, heart failure hospitalization, cardiovascular events, life studies, sinus rhythm maintenance, RAS inhibition, renin-angiotensin system
MeSH terms: Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Atenolol, Atrial Fibrillation, Cause of Death, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Prospective Studies, Risk Factors, Survival Rate, Hypertrophy, Left Ventricular, Losartan, Stroke, Angiotensin II Type 1 Receptor Blockers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks